4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference Oct 14, 2025 08:00AM
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) Sep 19, 2024 08:06AM
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) Jul 17, 2024 01:07PM
4D Molecular Therapeutics (FDMT) PT Raised to $38 at Chardan, 'Phase II wAMD Data Set Up a Competitive GT Profile' Feb 5, 2024 10:14AM
Chardan Capital Markets Starts 4D Molecular Therapeutics (FDMT) at Buy Jul 5, 2023 05:35AM


May 9, 2023 04:05PM 4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 5, 2023 05:43AM 4D Molecular Therapeutics Inc. (FDMT) Prices Upsized 7.5M Share Offering at $16/sh
May 4, 2023 09:04PM 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
May 4, 2023 04:09PM 4D Molecular Therapeutics Inc. (FDMT) Announces Proposed $100M Share Offering
May 4, 2023 04:08PM 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
Sep 20, 2022 04:15PM 4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
Sep 20, 2022 04:15PM 4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
Sep 29, 2021 04:01PM 4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference
Sep 29, 2021 04:01PM 4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference